Celigo Helping Move Research Forward to Find a Cure for Alzheimer’s

November is National Alzheimer's Disease Awareness Month and research into a cure for the disease is vigorous. In a recently published paper "CRISPR/Cas9-Correctable mutation-related molecular andphysiological phenotypes in iPSC-derived Alzheimer’s PSEN2N141I neurons" researchers used the Celigo image cytometer upstream of CRISPR/Cas9 to visualize and asses cell death related to the sensitivity of iPSC-derived PSEN2N1411 neurons in the presence of Aβ42 oligomer toxicity.

By |2017-11-07T10:53:34+00:00November 7th, 2017|Categories: Celigo User Publications|Tags: , , , |0 Comments

Celigo evaluates a plant extract for glioblastomoa multiforme treatment

At the Canary Center at Stanford for Early Cancer Detection, investigators studied how AshwaMAX (a steroidal lactone from a winter cherry plant, Withania somnifera, extract) might work as an oral treatment for those with the highly aggressive cancer glioblastoma multiforme (GBM). A heterogeneous disease, non-specific therapies for GBM have proven largely ineffective. Two patient-derived GBM lines (GBM2, GBM39) and one GBM cell line were cultured to create neurospheres that were then exposed to various concentrations of AshwaMAX.  Celigo measured cell proliferation and cell death via Trypan Blue staining. AshwaMAX inhibited the neurospheres at nanomolar concentrations. After additional work in vivo, [...]